Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)

Sanofi lands 3rd Covid-19 vac­cine man­u­fac­tur­ing part­ner as it works to push for­ward its own jab

As the de­mand for mR­NA-based Covid-19 vac­cines per­sists, Sanofi is jump­ing in­to the fray.

The French drug­mak­er has en­tered an agree­ment with Mod­er­na to man­u­fac­ture the com­pa­ny’s Covid-19 vac­cine. The agree­ment marks the third dif­fer­ent com­pa­ny Sanofi has paired with to man­u­fac­ture a Covid-19 vac­cine, since their own ef­fort to de­vel­op a pan­dem­ic in­oc­u­la­tion faced sig­nif­i­cant set­backs.

The com­pa­ny will per­form fill-and-fin­ish at its Ridge­field, NJ site to com­plete up to 200 mil­lion dos­es of the vac­cine. That will be­gin in Sep­tem­ber.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.